Recent News
|
Mar 18, 2026
Neuropeutics receiving funding through Regional Genomic Applications Partnership Program (GAPP) by Ontario Genomics Read More |
Mar 3, 2026
Half-Million Dollars Grant by ALS Canada and Brain Canada for the identification and validation of lead small molecule. Read More |
Jan 17, 2026
Peer-reviewed publication of small molecule 'JRMS' in the journal of Neurotherapeutics. Read More |
Dec 3, 2025
CSO Janice Robertson is delivering a plenary talk at the 36th International Symposium on ALS/MND in San Diego, USA |
|
|
|
|
April 1-5, 2024
Neuropeutics presents JRMS-22 at AD/PD™ 2025 Alzheimer's & Parkinson's Diseases Conference in Vienna, Austria. Read more |
|
|
|
October 17, 2024
Neuropeutics is 1 of 100 Innovative Companies Advancing to the Entrepreneurship World Cup Global Finals Read more |
|
September 27, 2024
Neuropeutics selected among 'Sweet 16' to pitch at Sweet Biopharma day. Read more |
September 21, 2024
Neuropeutics presents at 2024 International Society for Frontotemporal Dementias. Read more |
August 15, 2024
Neuropeutics presented 'Breaking the walls of Neurodegeneration' winning 3rd place at Falling Walls Lab Toronto. Read more |
August 10, 2024
Neuropeutics wins Canadian National Finals becoming 1 of top 100 global finalists for 2024 EWC. Read more Read more |
August 3, 2024
Neuropeutics selected as a Canadian Finalist for the 2024 Entrepreneurship World Cup (EWC). Read more |
July 10, 2024
Neuropeutics selected as a finalist for 14th annual LiONS LAIR Pitch Competition. Read more |
March 29, 2024
Neuropeutics is exhibiting at DiscoveryX hosted by Ontario Center of Innovation. Read more |
March 7, 2024
Neuropeutics wins 2nd Place Award and People's Choice Award at Desjardins Pitch Competition. Read more |
February 20, 2024
Neuropeutics selected as a finalist for Early-Stage Desjardins Pitch Competition. |
October 25, 2023
Neuropeutics’ founders awarded the Connaught Innovation Award. |
September 12, 2023
Neuropeutics wins People Choice Award at Lab2Market Launch National Health Cohort Virtual Pitch. |
September 6, 2023
Neuropeutics accepted into the CDL program, Neuro Stream in Toronto. |
July 7, 2023
Neuropeutics participates in Summer by Design program. |
July 1, 2023
Dr. Marc Shenouda awarded AFTD Holloway Postdoctoral Fellowship to continue developing therapeutics for ALS/FTD. |
June 6, 2023
Neuropeutics joins Lab2Market Launch summer accelerator. |
May 16, 2023
Neuropeutics’ founders present “Small Molecule Targeting of {IP Protein} prevents and reverses TDP-43 aggregation in vitro and in vivo” at 2nd ALS Drug Development Summit. |
May 8, 2023
Neuropeutics wins 2nd place in KITE ICAIR Pitch Concept. |
